Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNX Athenex		$0.95	$0.20 ▼ $23.80	$1.76M	1.36	194,316 shs	1.88 million shs
AVDL Avadel Pharmaceuticals	$17.38 -3.4%	$15.49	$9.50 ▼ $18.85	$1.57B	1.6	1.24 million shs	1.11 million shs
FLXN Flexion Therapeutics	$9.12	$9.20	$4.30 ▼ $13.66	$458.93M	1.53	1.18 million shs	N/A
GMTX Gemini Therapeutics	$30.02 -0.9%	$56.14	$1.16 ▼ $14.10	$1.30B	-0.12	189,291 shs	315,937 shs
MDVL MedAvail		$3.31	$1.31 ▼ $20.89	$2.91M	0.76	261,432 shs	245,100 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNX Athenex	0.00%	0.00%	0.00%	0.00%	-86.09%
AVDL Avadel Pharmaceuticals	-3.39%	+8.90%	+10.00%	+16.02%	+71.40%
FLXN Flexion Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
GMTX Gemini Therapeutics	-0.86%	-4.76%	-54.54%	-51.64%	+18.19%
MDVL MedAvail	0.00%	0.00%	0.00%	-34.66%	+525.22%

You’re invited: Biggest crypto event of 2024 (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNX Athenex	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	3.128 of 5 stars	4.5	2.0	0.0	0.0	3.2	1.7	0.6
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MDVL MedAvail	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNX Athenex	N/A	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	3.00	Buy	$22.57	29.87% Upside
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A
MDVL MedAvail	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest AVDL, FLXN, GMTX, MDVL, and ATNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2024	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
3/5/2024	AVDL Avadel Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
3/5/2024	AVDL Avadel Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$18.00 ➝ $23.00
3/5/2024	AVDL Avadel Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$27.00 ➝ $29.00
3/5/2024	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $25.00
3/5/2024	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
2/6/2024	AVDL Avadel Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNX Athenex	$102.82M	0.00	N/A	N/A	($3.07) per share	0.00
AVDL Avadel Pharmaceuticals	$27.96M	56.30	N/A	N/A	$0.98 per share	17.73
FLXN Flexion Therapeutics	$85.55M	5.36	N/A	N/A	($0.34) per share	-26.82
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
MDVL MedAvail	$43.33M	0.00	N/A	N/A	$13.01 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNX Athenex	-$103.43M	-$15.88	N/A	N/A	N/A	-86.31%	-727.79%	-44.44%	N/A
AVDL Avadel Pharmaceuticals	-$160.28M	-$2.04	N/A	20.94	N/A	N/A	-198.06%	-84.51%	5/2/2024 (Estimated)
FLXN Flexion Therapeutics	-$113.71M	-$2.01	N/A	N/A	N/A	-100.32%	N/A	-44.26%	N/A
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
MDVL MedAvail	-$47.62M	-$28.72	N/A	N/A	N/A	-192.97%	-218.10%	-103.45%	N/A

Latest AVDL, FLXN, GMTX, MDVL, and ATNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/4/2024	Q4 2023	AVDL Avadel Pharmaceuticals	-$0.28	-$0.32	-$0.04	-$0.29	$17.41 million	$19.45 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNX Athenex	N/A	N/A	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
MDVL MedAvail	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNX Athenex	3.08	1.09	0.72
AVDL Avadel Pharmaceuticals	N/A	3.64	3.36
FLXN Flexion Therapeutics	N/A	4.38	4.05
GMTX Gemini Therapeutics	N/A	71.49	71.49
MDVL MedAvail	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ATNX Athenex	30.48%
AVDL Avadel Pharmaceuticals	69.19%
FLXN Flexion Therapeutics	90.01%
GMTX Gemini Therapeutics	75.42%
MDVL MedAvail	N/A

Insider Ownership

Company	Insider Ownership
ATNX Athenex	9.20%
AVDL Avadel Pharmaceuticals	4.00%
FLXN Flexion Therapeutics	9.13%
GMTX Gemini Therapeutics	12.90%
MDVL MedAvail	1.50%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNX Athenex	652	8.66 million	7.87 million	Optionable
AVDL Avadel Pharmaceuticals	154	90.58 million	86.95 million	Optionable
FLXN Flexion Therapeutics	257	50.32 million	45.73 million	Optionable
GMTX Gemini Therapeutics	31	43.33 million	37.74 million	Not Optionable
MDVL MedAvail	279	1.61 million	1.59 million	No Data

AVDL, FLXN, GMTX, MDVL, and ATNX Headlines

Source	Headline
	Delhi Bank Corp DWNX morningstar.com - April 18 at 11:50 PM
	US Stocks Mixed; Trimble Issues Weak Outlook msn.com - February 12 at 5:26 PM
	U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.33% msn.com - February 12 at 5:26 PM
	MedAvail Holdings Faces Nasdaq Delisting After Bankruptcy msn.com - February 9 at 9:52 AM
	Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected msn.com - February 8 at 2:26 PM
	US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data msn.com - February 8 at 9:25 AM
	U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.37% msn.com - February 6 at 5:20 PM
	U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.37% msn.com - February 6 at 5:20 PM
	MedAvail Holdings Files for Chapter 7 Bankruptcy msn.com - February 3 at 9:41 AM
	Dow Falls 150 Points; US Economy Adds 353,000 Jobs In January msn.com - February 2 at 12:27 PM
	Medavail Holdings Inc (MDVL) investing.com - January 31 at 9:49 AM
	MedAvail Announces Agreement with New Orleans-Based St. Thomas Community Health Centers for Deployment of Two M4 MedCenters finance.yahoo.com - November 28 at 9:23 AM
	MedAvail Holdings Inc Ordinary Shares MDVL morningstar.com - November 18 at 5:23 PM
	MedAvail Holdings, Inc.: MedAvail Receives Nasdaq Notification of Non-Compliance Related to Delayed Quarterly Report on Form 10-Q finanznachrichten.de - November 18 at 7:21 AM
	MedAvail receives non-compliance notice from Nasdaq msn.com - November 17 at 8:47 PM
	MedAvail Receives Nasdaq Notification of Non-Compliance Related to Delayed Quarterly Report on Form 10-Q benzinga.com - November 17 at 8:47 PM
	MedAvail Receives Nasdaq Notification of Non-Compliance Related to Delayed Quarterly Report on Form 10-Q finance.yahoo.com - November 17 at 8:47 PM
	MedAvail Announces Agreement with ASP Cares for Deployment of Ten M4 MedCenters finance.yahoo.com - November 17 at 10:46 AM
	MDVL, BACK and FTEL are among mid-day movers msn.com - November 10 at 4:00 PM
	MedAvail to Participate in H.C. Wainwright 25th Annual Global Investment Conference finance.yahoo.com - August 30 at 9:10 AM
	Potential Upside For MedAvail Holdings, Inc. (NASDAQ:MDVL) Not Without Risk finance.yahoo.com - August 16 at 7:47 AM
	MedAvail Holdings, Inc.: MedAvail Reports Second Quarter 2023 Financial Results finanznachrichten.de - August 15 at 9:28 AM
	MedAvail Reports Second Quarter 2023 Financial Results finance.yahoo.com - August 14 at 6:26 PM
	MedAvail Announces Agreement with Dallas-Based Oak Lawn Pharmacy for Deployment of Ten M4 MedCenters finance.yahoo.com - August 4 at 6:13 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Athenex

NASDAQ:ATNX

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Avadel Pharmaceuticals

NASDAQ:AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Flexion Therapeutics

NASDAQ:FLXN

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

Gemini Therapeutics

NASDAQ:GMTX

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

MedAvail

NASDAQ:MDVL

MedAvail Holdings, Inc., a technology-enabled retail pharmacy technology and services company, develops and commercializes self-service pharmacy, mobile application, and kiosk solutions in the United States and Canada. It offers a pharmacy technology solution, including the MedAvail MedCenter, which enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and other location where onsite prescription dispensing is desired, as well as establishes an audio-visual connection to a live pharmacist enabling prescription drug dispensing to occur directly to a patient with real-time supervision by a pharmacist. The company is headquartered in Phoenix, Arizona. On February 2, 2024, MedAvail Holdings, Inc along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial